Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
- 31 May 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 7171-7179
Abstract
Background: Despite treatment with renin–angiotensin system inhibitors (RASis) and sodium–glucose cotransporter 2 inhibitors (SGLT2is), diabetic kidney disease (DKD) continues to exhibit substantial residual renal risk. The renoprotective effects of adding finerenone to dual therapy remain incompletely characterised. Methods: A total of 255 patients with DKD receiving combined RASi and SGLT2i therapy were analysed by intention‐to‐treat as triple combination therapy (TCT) with finerenone or dual combination therapy (DCT) alone. The outcomes were longitudinal changes in proteinuria, serum potassium and estimated glomerular filtration rate (eGFR) slope, including total eGFR slope over 24 months and the post–initial dip eGFR slope from 3 to 24 months, evaluated before and after propensity score (PS) matching. Results: Over a 24‐month follow‐up period, TCT was associated with a greater and sustained reduction in proteinuria compared with DCT, with significant reductions of 47% at 24 months ( p = 0.028). Although the total eGFR slope did not differ significantly between groups, the post–initial dip slope was significantly improved in the TCT group, with an attenuation of annual eGFR decline by approximately 1.31 mL/min/1.73 m 2 /year (95% CI: 0.25 to 2.36) compared with DCT ( p = 0.015). After PS matching, this association remained significant (between‐group difference 1.45 mL/min/1.73 m 2 /year; 95% CI: 0.32–2.58; p = 0.012). Serum potassium increased modestly in the early phase of TCT but stabilised thereafter, with no significant difference between groups at 24 months. Conclusions: Among patients with DKD receiving RASi and SGLT2i therapy, the addition of finerenone was associated with greater proteinuria reduction and a significant improvement in the post–initial dip eGFR slope, suggesting that TCT may offer an additional renoprotective strategy in DKD.Keywords
This publication has 36 references indexed in Scilit:
- Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulationNature Communications, 2025
- Finerenone and Kidney Outcomes in Patients With Heart FailureJACC, 2024
- Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trialNature Medicine, 2024
- Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m2Metabolism Open, 2023
- A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesKidney International, 2022
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyKidney International Reports, 2021
- Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?Hypertension Research, 2019
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney diseaseHypertension Research, 2018
- Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney diseaseKidney International, 2006
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001